Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust®) Versus Herceptin® in Breast Cancer (Q63401729)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust®) Versus Herceptin® in Breast Cancer |
clinical trial |
Statements
A Phase III, Randomized, Two-armed, Patient-outcome Assessor-data Analyzer Blinded, Parallel Active Controlled Non-Inferiority Clinical Trial Study of AryoTrust™ (Aryogen Trastuzumab ) Efficacy and Safety in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Comparison to Herceptin® (Genentech/Roche) Control. (English)
0 references
9 July 2016
0 references
6 March 2019
0 references
108
0 references
18 year
0 references
70 year
0 references